1. Home
  2. LCFY vs ALZN Comparison

LCFY vs ALZN Comparison

Compare LCFY & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Locafy Limited

LCFY

Locafy Limited

HOLD

Current Price

$4.20

Market Cap

8.4M

Sector

N/A

ML Signal

HOLD

Logo Alzamend Neuro Inc.

ALZN

Alzamend Neuro Inc.

HOLD

Current Price

$1.06

Market Cap

7.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCFY
ALZN
Founded
2009
2016
Country
Australia
United States
Employees
18
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.4M
7.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LCFY
ALZN
Price
$4.20
$1.06
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
13.6K
177.9K
Earning Date
03-13-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
22.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$0.51
52 Week High
$13.98
$8.22

Technical Indicators

Market Signals
Indicator
LCFY
ALZN
Relative Strength Index (RSI) 50.06 26.79
Support Level $4.07 N/A
Resistance Level $4.80 $2.59
Average True Range (ATR) 0.24 0.20
MACD -0.07 -0.10
Stochastic Oscillator 31.37 6.54

Price Performance

Historical Comparison
LCFY
ALZN

About LCFY Locafy Limited

Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.

About ALZN Alzamend Neuro Inc.

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Share on Social Networks: